Loading…
Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.
Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.
Customers pay monthly or by plan for medication shipped from its own pharmacies, with the consultation by affiliated clinicians included, so revenue is mostly recurring and depends on subscriber retention and what each subscriber buys. Online advertising drives customer acquisition. Some products are compounded versions of branded drugs, a regulatory-sensitive area.
Moat: narrow (brand, scale, data). Strong direct-to-consumer brand and marketing scale in a category with growing but not-yet-entrenched telehealth competitors.
Headquarters: San Francisco, California, USA · Founded: 2017 · Employees: 2,442
Size Hims & Hers Health (HIMS) is a United States Health Care company (Medical/Nursing Services) with a market value of $6.07B, the 1055th largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.00 on 6 Nov 2026.
Performance Over six months the shares fell 8.0%, against +29.6% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 28.0% over the last twelve months (peer median +11.7%); the operating margin is 0.0% (peer median 10.5%).
Valuation It trades at 128.9× forward earnings against a peer median of 21.1× (3rd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 55% a year for seven years (Req g). Recent delivered growth is +74%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.1 points below its cost of capital (15.0% WACC).
Credit Hims & Hers Health has 1 bond outstanding ($1.00B).
Short interest Short interest is 23.8% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.35B | $1.48B | $872M | $527M |
| Revenue growth | — | +59% | +69% | +65% | — |
| Gross profit | $1.40B | $1.39B | $970M | $705M | $401M |
| EBITDA | $86.5M | $176M | $85.1M | -$23.9M | -$61.0M |
| Net income | -$142M | $128M | $126M | -$23.5M | -$65.7M |
| Free cash flow | $64.7M | $57.4M | $198M | $47.0M | -$33.8M |
| Capital expenditure | $202M | $243M | $52.8M | $26.5M | $7.25M |
| Total debt | $1.55B | $1.12B | $11.3M | $9.95M | $5.31M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hims & Hers Health HIMS | $6.07B | -8% | +28% | 0% | 128.9× | 54.9% |
| Teladoc Health TDOC | $1.60B | +21% | -2% | -5% | n/a | -5.2% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 28.9× | 5.9% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| GoodRx GDRX | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HIMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | +10.1% | lowest of 21 |
| 6-month return | -8.0% | +29.6% | 3rd lowest of 20 |
| Distance from 52-week high | -40.9% | -10.7% | 2nd lowest of 21 |
| Revenue growth (TTM) | +28.0% | +11.7% | 3rd highest of 21 |
| Operating margin | 0.0% | 10.5% | lowest of 21 |
| Forward P/E | 128.9× | 21.1× | 3rd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 54.9% | 11.8% | most demanding of 19 |
| Growth delivered (Del g) | +73.6% | +12.5% | 2nd highest of 19 |
| Hurdle (Req g minus delivered) | -18.7 pp | +0.3 pp | 2nd least demanding of 19 |
| ROIC minus cost of capital | -15.1 pp | +1.7 pp | lowest of 21 |
| Net debt / EBITDA | 8.2× | 2.8× | most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hims & Hers Health HIMS | United States | $6.07B | -8% | +28% | 0% | 128.9× | 54.9% | +73.6% |
| RadNet RDNT | United States | $5.98B | +31% | +19% | 5% | 129.7× | 41.8% | +13.7% |
| Concentra Group Holdings Parent CON | United States | $5.38B | +75% | +14% | 17% | 24.5× | 3.9% | +7.9% |
| BillionToOne BLLN | United States | $5.38B | +54% | +90% | 11% | 144.4× | 26.8% | +90.1% |
| Sonic Healthcare SHL.AX | Australia | $6.87B | +6% | +14% | 9% | 16.8× | 8.6% | +3.5% |
| Lifestance Health LFST | United States | $5.26B | +79% | +20% | 5% | 62.6× | 37.8% | +30.4% |
| Option Care Health OPCH | United States | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% | +13.2% |
| Medicover MCOV-B.ST | Sweden | $4.14B | +36% | +6% | 7% | 38.3× | 20.8% | +20.2% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% | +11.8% |
| Ensign ENSG | United States | $10.6B | +6% | +17% | 9% | 21.1× | 12.0% | +16.5% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| DaVita DVA | United States | $12.0B | -4% | +6% | 15% | 11.9× | -1.1% | +3.4% |
| Aier Eye Hospital 300015.SZ | China | $12.5B | -16% | +5% | 21% | 29.5× | 11.7% | +13.4% |
| Fresenius Medical Care FME.DE | Germany | $12.6B | +14% | 0% | 11% | 10.4× | -3.6% | +1.9% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| BrightSpring Health Services BTSG | United States | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% | +18.3% |
| Encompass Health EHC | United States | $13.5B | +30% | +9% | 18% | 20.5× | 5.6% | +5.0% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Solventum SOLV | United States | $15.4B | +23% | -1% | 8% | 12.2× | n/a | n/a |
Hims & Hers Health has 1 bond outstanding with $1.00B face value.